Pharmafile Logo
Pharmafocus logo
Advanced Search

gene therapy

Showing 15 posts of 43 posts found.

Evox Therapeutics enters agreement for next generation gene therapy for heart disease

August 4, 2023
Research and Development Cardiology, Evox Therapeutics, Icahn Mount Sinai, cvd, gene therapy

Evox Therapeutics has announced a research collaboration and option agreement with the Icahn School of Medicine at Mount Sinai (Icahn …

News

SNIPR Biome reports positive findings for first-in-human, CRISPR-based microbial gene therapy

May 31, 2023
Research and Development Infections and infestations, SNIPR Biome, clinical trial, crispr, gene therapy

Danish CRISPR-based microbial gene therapy company SNIPR Biome have announced positive interim data from its phase 1 clinical trial with …

News

Rocket Pharmaceuticals granted FDA RMAT designation for gene therapy

May 24, 2023
Medical Communications FDA, Haematology, RMAT, Rocket Pharmaceuticals, gene therapy

Rocket Pharmaceuticals, a US-based biotechnology company, has announced that it has received US Food and Drug Administration (FDA) Regenerative Medicine …

News
brano-mm1vipqd0oa-unsplash

Krystal Biotech secures FDA approval for redosable topical gene therapy

May 22, 2023
Medical Communications FDA, Krystal Biotech, Paediatrics, dystrophic epidermolysis bullosa, gene therapy

US-based biotech company Krystal Biotech has announced that the US Food and Drug Administration (FDA) has approved its topical gene …

News

Nemours Children’s Health selected to conduct first gene therapy for Morquio A syndrome

May 17, 2023
Research and Development Morquio A syndrome, NIH, Nemours Children's Health, Paediatrics, gene therapy

Nemours Children’s Health, based in Delaware, US, has been chosen by the Foundation for the National Institutes of Health (FNIH) …

News

FDA pre-meeting report raises concerns over Sarepta’s gene therapy for Duchenne muscular dystrophy

May 11, 2023
Medical Communications Duchenne Muscular Dystrophy, FDA, Musculo-skeletal disorder, Sarepta Therapeutics, gene therapy

The US Food and Drug Administration (FDA) has released a report in preparation for its 12 May decision on Sarepta …

News
biogen_austria_238

Biogen and Capsigen to collaborate on novel gene therapies

May 11, 2021
Manufacturing and Production gene therapy

Biogen and Capsigen have announced a research collaboration to engineer novel adeno-associated virus (AAV) capsids that have the potential to …

News
novartis_outside_1

Novartis reveals hard-hitting five-year data for its gene therapy Zolgensma in spinal muscular atrophy

March 25, 2020
Research and Development Novartis, Zolgensma, gene therapy, pharma, spinal muscular atrophy

Novartis has revealed five-year data on its gene therapy Zolgensma, boasting that the one-time infusion demonstrated “rapid, significant and clinically …

News
bluebird_bio_external_durham_nc_manufacturing

Bluebird bio’s Lenti-D gene therapy shows promise in cerebral adrenoleukodystrophy

September 23, 2019
Research and Development, Sales and Marketing Bluebird Bio, cerebral adrenoleukodystrophy, gene therapy, pharma

Bluebird bio has revealed updated data for its investigational Lenti-D gene therapy in the treatment of cerebral adrenoleukodystrophy (CALD), a …

News

NICE recommends Novartis’ gene therapy Luxturna for inherited retinal dystrophy

September 4, 2019
Research and Development, Sales and Marketing Luxturna, NHS, NICE, UK, gene therapy, pharma

NICE has chosen to recommend the use of Novartis’ one-time gene therapy Luxturna (voretigene neparvovec) for use on the NHS …

News
novartis_window

Novartis hid faulty data from FDA over $2.1 million gene therapy Zolgensma

August 7, 2019
Research and Development AveXis, FDA, Novartis, Zolgensma, gene therapy, pharma

Novartis hid faulty data from the FDA until their drug was approved, according to a statement from Dr Peter Marks, …

News

EMA approves Bluebird Bio’s gene therapy Zynteglo

June 4, 2019
Manufacturing and Production Bluebird Bio, European comission, gene therapy, health, pharma

The European Commission has granted a conditional marketing authorisation to bluebird bio’s gene therapy Zynteglo. The Massachusetts-based firm’s one time …

News

Doctors cure ‘bubble boy syndrome’ using modified version of HIV

April 18, 2019
Research and Development HIV, SCID-X1, gene therapy, immunodeficiency, immunology

Doctors at St. Jude Children’s Research Hospital have been able to treat patients with X-linked severe combined immunodeficiency (SCID-X1) – …

News
credit_-_daniel_leal-olivas-afp

CHMP recommendation for bluebird bio’s gene therapy in β-thalassaemia

April 1, 2019
Research and Development, Sales and Marketing Bluebird Bio, CHMP, EMA, Zynteglo, gene therapy, β-thalassaemia

Massachusetts-based bluebird bio has taken a significant leap forward in its pursuit of regulatory authorisation for its first gene therapy, …

News

Roche set to acquire Spark Therapeutics in $4.8 billion deal

February 25, 2019
Sales and Marketing Roche, Spark Therapeutics, acquisition, gene therapy, pharma

Roche is set to fully acquire gene therapy Spark Therapeutics after entering into a definitive merger agreement, after the Boards …

News

Latest content

FDA grants ODD to Nexcella’s NXC-201 as treatment for amyloid light chain amyloidosis

September 22, 2023

AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan performs well in phase 3 trial

September 22, 2023

Novo Nordisk partners with UNICEF to prevent global childhood obesity

September 21, 2023

EC approves Menarini Group’s Orserdu for breast cancer treatment

September 21, 2023

Pharmanovia acquires CNS portfolio from Sanofi

September 20, 2023